Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03044223 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

Study acronym: MIPSA
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 17, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Nov 2018 to Nov 2025
    • Study completion date: Dec 2018 to Dec 2026
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.
Trial Details
NCT Number NCT03044223
Lead Sponsor University of Ulm
Conditions
(from sponsor)		 Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia, Pseudomonal Bacteraemia, Pseudomonas Urinary Tract Infection, Pseudomonas Gastrointestinal Tract Infection, Sepsis, Sepsis, Severe +1 more
Related terms Critical Illness, Pneumonia, Pseudomonas Infections, Sepsis
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov